Summary
Neonatal opioid withdrawal syndrome is the constellation of signs that appears when an infant with in-utero opioid exposure is separated from that supply at birth [1]. Care has moved decisively toward a function-based assessment and nonpharmacologic-first management, and the Eat, Sleep, Console approach has changed how these infants are evaluated and treated [1][2].
- The syndrome combines central nervous system irritability, autonomic instability, and gastrointestinal dysfunction, appearing within the first days of life with a timing that depends on the specific opioid [1].
- Nonpharmacologic care is the foundation and the first-line treatment. A low-stimulation environment, rooming-in, breastfeeding when not contraindicated, and parental presence reduce the severity of expressed withdrawal [1][2].
- The Eat, Sleep, Console approach assesses whether the infant can feed, sleep, and be consoled rather than tallying individual signs, and it reduces the use of pharmacologic treatment and the length of stay compared with usual care [2].
- When an infant cannot eat, sleep, or be consoled despite optimized nonpharmacologic care, opioid pharmacotherapy, usually morphine or methadone, is added [1].
Caution. Neonatal opioid withdrawal syndrome and iatrogenic withdrawal from sedation and analgesia in the intensive care unit are different clinical situations that use different tools. The Finnegan-derived and Eat, Sleep, Console approaches were developed for in-utero opioid exposure, whereas iatrogenic withdrawal after prolonged sedation is assessed with a dedicated tool [1].
Assessment
Two assessment philosophies coexist. The traditional Finnegan-based scoring quantifies a long list of withdrawal signs, an approach codified in earlier national guidance, while the Eat, Sleep, Console approach asks the functional questions that actually drive treatment decisions [1][2][3].
| Approach |
What it measures |
Treatment trigger |
| Finnegan-based scoring |
Weighted tally of withdrawal signs |
Serial scores above a threshold [1] |
| Eat, Sleep, Console |
Ability to feed, sleep, and be consoled |
Failure in a domain despite nonpharmacologic care [2] |
The traditional scoring approach captures the severity and range of signs when a structured sign-based assessment is used.
Score withdrawal severity in the Neonatal Abstinence Score →
For an infant in the intensive care unit developing withdrawal after prolonged opioid or benzodiazepine sedation, the assessment tool is different and is designed for iatrogenic withdrawal.
Assess iatrogenic withdrawal in WAT-1 →
Management
Nonpharmacologic care comes first and continues throughout, regardless of whether medication is later added [1][2]. Keeping the mother and infant together, minimizing stimulation, supporting feeding, and involving the family directly reduce the intensity of withdrawal and the need for medication [1][2].
The Eat, Sleep, Console approach operationalizes this by making the assessment itself function-based. A large randomized trial found that infants managed with this approach were ready for discharge sooner and received pharmacologic treatment less often than those managed with usual Finnegan-based care, without an increase in adverse outcomes over the follow-up period [2]. The result reframed the goal from suppressing a score to restoring the infant's ability to feed, sleep, and be comforted.
When pharmacologic treatment is needed, an opioid is the primary agent, titrated to restore function and then weaned as the infant stabilizes [1]. Discharge planning is part of treatment and includes maternal support, safe-sleep counseling, linkage to early intervention, and coordinated outpatient follow-up, because the infant's course continues well past the birth hospitalization [1].
References
- Patrick SW, Barfield WD, Poindexter BB; Committee on Fetus and Newborn. Neonatal opioid withdrawal syndrome. Pediatrics. 2020;146(5):e2020029074. doi:10.1542/peds.2020-029074
- Young LW, Ounpraseuth ST, Merhar SL, et al. Eat, Sleep, Console approach or usual care for neonatal opioid withdrawal. N Engl J Med. 2023;388(25):2326-2337. doi:10.1056/NEJMoa2214470
- Hudak ML, Tan RC; Committee on Drugs; Committee on Fetus and Newborn. Neonatal drug withdrawal. Pediatrics. 2012;129(2):e540-e560. doi:10.1542/peds.2011-3212